06-Oct-2022 | Facts and Factors
According to Facts and Factors, the global anticoagulant drugs market size was worth around USD 36.5 billion in 2021 and is predicted to grow to around USD 68.9 billion by 2028 with a compound annual growth rate (CAGR) of roughly 9.5% between 2022 and 2028.
Anticoagulants are drugs that work to stop the blood from clotting or thickening. Anticoagulants protect patients from potentially fatal ailments like heart attacks and pulmonary embolisms.
Browse the full “Anticoagulant Drugs Market Size, Share, Growth Analysis Report By Drug Class (Heparins, Factor Xa Inhibitor, Warfarin, Direct Thrombin Inhibitor, and Others), By Route of Administration (Oral and Injectable), By Application (Atrial Fibrillation/Flutter, Venous Thromboembolism, Coronary Heart Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/anticoagulant-drugs-market
One of the main factors driving the global market for anticoagulants is the growing elderly population. The development of novel oral anticoagulant medications and rising pharmaceutical R&D expenditures have also contributed to the expansion of this industry. One major trend in the global market for anticoagulants is an increase in mergers and acquisitions of pharmaceutical manufacturing firms. However, the strict rules imposed by various governments, the greater cost of NOACs, and the absence of NOAC antidotes restrain the expansion of the global anticoagulants drugs market. Additionally, the possibility of difficulties and adverse effects from using oral anticoagulants restrains the development of the worldwide anticoagulants drugs market.
The anticoagulant industry is being shaped by the current clinical studies of anticoagulant therapies for COVID-19. Major anticoagulant companies are focusing on setting up clinical studies of anticoagulant drugs to reduce the risk of COVID-19-related blood clotting in adults. For instance, the third and last Phase III clinical trial using blood thinners (anticoagulants) to prevent life-threatening blood clots in older adults with COVID-19 began in March 2021 at the National Institutes of Health (NIH) in the USA. Concerns about the use of anticoagulants, sometimes referred to as antithrombotics, in the treatment of COVID-19 will be allayed by the ACTIV-4 studies. Thus, the COVID-19 pandemic positively influenced the anticoagulant drug market.
The global anticoagulant drugs market is segmented based on drug class, route of administration, application, distribution channel, and region.
The global market is divided into heparins, factor Xa inhibitors, warfarin, direct thrombin inhibitors, and others based on the drug class. Heparins held the biggest market share in 2021, and it is anticipated that this segment would continue to dominate during the forecast period. Heparin is a drug that helps a variety of people prevent blood clots from developing. These conditions include deep vein thrombosis, acute coronary syndrome, atrial fibrillation, pulmonary embolism, and unstable angina. Cardiac surgeons utilize this blood thinner to treat these conditions as well as other conditions.
The global anticoagulant drugs market is divided into oral and injectable segments based on the route of indication. Throughout the projected period, the oral segment is expected to rule the market. The oral route of drug delivery is one of the most well-liked approaches. Direct oral anticoagulants (DOACs) provide greater absorption and fewer drug interactions. Outside influences like food and alcohol have no impact on them. Oral anticoagulants will be more in demand as stroke and systemic embolism risk factors for atrial fibrillation patients rise.
The market for anticoagulants is divided into atrial fibrillation/flutter, venous thromboembolism, coronary heart disease, and others based on the application. With over 30% of the market share in 2021, the atrial fibrillation/flutter category was dominant, and it is anticipated that this trend would continue during the forecast period. The incidence of AFib is increasing alarmingly swiftly. Many public and private healthcare groups are working to increase public knowledge of different cardiac issues. According to the Stroke Association, over a million people in the UK suffer from atrial fibrillation. Anticoagulants are frequently used to treat this illness.
Hospital pharmacies, retail pharmacies, and online pharmacies are the three categories into which the global anticoagulant drugs market is split based on distribution channels. The market share leader in 2021 was the segment of hospital pharmacies, and this trend is anticipated throughout the forecast period. Hospital pharmacies have several benefits, including easier pharmaceutical access. Since these departments have a more advanced infrastructure and medical staff, a major proportion of CVD patients visit hospital outpatient departments (OPDs) for treatment and pharmaceutical prescriptions. More patients will choose to obtain their treatments at hospitals to receive high-quality care, which will result in a significant increase in the sales of anticoagulants across all in-house pharmacies.
The market for anticoagulant drugs is divided into five regions based on geography: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. During the forecast period, Europe is anticipated to increase at the greatest CAGR. The increase in the number of elderly people in the area is thought to be the cause of the rise. For instance, the World Bank estimates that 21.98% of Germany's population was 65 years of age or older in 2021. The need for anticoagulants has increased as a result of this issue. The elderly population in the area is becoming more and more in need of non-invasive, improvised treatments. A positive increase in new medication deals between governments and healthcare institutions is also being seen in the region.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 36.5 Billion |
Projected Market Size in 2028 |
USD 68.9 Billion |
CAGR Growth Rate |
9.5% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Abbott Laboratories, Aspen Holdings, Sanofi, Pfizer Inc, Alexion Pharmaceuticals Inc., Leo Pharma AS, Dr. Reddy’s Laboratories, and others. |
Key Segment |
By Drug Class, Route of Administration, Application, Distribution Channel, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The global anticoagulant drugs market is dominated by players like Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Abbott Laboratories, Aspen Holdings, Sanofi, Pfizer, Inc, Alexion Pharmaceuticals Inc., Leo Pharma AS, and Dr. Reddy’s Laboratories, among others.
Recent Development:
In September 2020, an agreement was signed by Mylan N.V. to acquire Aspen Pharmacare Holdings to get aid in positioning one of the largest suppliers of injective anticoagulants to customers in the Europe region.
The global anticoagulant drugs market is segmented as follows:
By Drug Class
- Heparins
- Factor Xa Inhibitor
- Warfarin
- Direct Thrombin Inhibitor
- Others
By Route of Administration
By Application
- Atrial Fibrillation/Flutter
- Venous Thromboembolism
- Coronary Heart Disease
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
